Synta And Roche Agree To Co-Develop Anti-Inflammatory Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal for Synta’s CRAC channel inhibitor brings $25 million upfront plus potential for $1 billion in milestones.